Effectiveness and Safety of Direct Oral Anticoagulants vs. Warfarin and Recurrence After Discontinuation in Patients With Acute Venous Thromboembolism in the Real World
| Autor: | Tetsumin Lee, Toshihiro Nozato, Toru Obayashi, Nobuhiro Hara, Masashi Nagase, Ryoichi Miyazaki, Yasutoshi Nagata, Takamichi Miyamoto, Kentaro Mitsui, Giichi Nitta, Keita Watanabe, Sho Nagamine, Masakazu Kaneko, Takashi Ashikaga, Tomofumi Nakamura, Shinichiro Okata, Mao Terui Matsuyama |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
medicine.medical_specialty
Multivariate analysis Administration Oral Hemorrhage Recurrence Internal medicine Humans Medicine cardiovascular diseases Retrospective Studies Venous Thrombosis business.industry Incidence (epidemiology) Warfarin Anticoagulants Retrospective cohort study Venous Thromboembolism General Medicine medicine.disease Pulmonary embolism Discontinuation Cohort Cardiology and Cardiovascular Medicine business Venous thromboembolism medicine.drug |
| Zdroj: | Circulation Journal. 86:923-933 |
| ISSN: | 1347-4820 1346-9843 |
| DOI: | 10.1253/circj.cj-21-0588 |
| Popis: | BACKGROUND The efficacy of direct oral anticoagulants (DOACs) compared with warfarin for the treatment of venous thromboembolism (VTE), and the recurrence of VTE after discontinuation of anticoagulation therapy in research are limited.Methods and Results:This retrospective study enrolled 893 patients with acute VTE between 2011 and 2019. The cohort was divided into the transient risk, unprovoked, continued cancer treatment, and cancer remission groups. The following were compared between DOACs and warfarin: composite outcome of all-cause death, VTE recurrence, bleeding and composite outcome of VTE-related death, recurrence and bleeding. In the continued cancer treatment group, more bleeding was seen in warfarin-treated patients than in patients treated with DOACs (53.2% vs. 31.2%, [P=0.048]). In addition, composite outcome of VTE-related death and recurrence after discontinuation of anticoagulation therapy (n=369) was evaluated. The continued cancer treatment group (multivariate analysis: HR: 3.62, 95% CI: 1.84-7.12, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|